Skip to main content

Table 5 Sensitivity of the stool DNA test targeting methylated SDC2 in different characteristics of CRC patients

From: A novel method for early detection of colorectal cancer based on detection of methylation of two fragments of syndecan-2 (SDC2) in stool DNA

  SDC2-Combine A&B Sensitivity (95% CI) SDC2-A Sensitivity (95% CI) SDC2-B Sensitivity (95% CI) P value
Gender
Male 86.00% (73.50–93.36%) 82.00% (68.98–90.46%) 84.00% (71.22–91.93%) 0.862
Female 88.46% (76.66–94.97%) 84.62% (72.21–92.26%) 86.54% (74.42–93.63%) 0.848
Age
 < 35 100.00% (38.25–100.00%) 100.00% (38.25–100.00%) 100.00% (38.25–100.00%) /
35–45 70.00% (39.23–89.67%) 70.00% (39.23–89.67%) 70.00% (39.23–89.67%) 1.000
46–55 92.31% (64.58–99.99%) 84.62% (56.54–96.90%) 76.92% (49.06–92.50%) 0.554
 > 55 88.16% (78.78–93.86%) 84.21% (74.24–90.89%) 88.16% (78.78–93.86%) 0.708
Clinical stage
0 50.00% (15.00–85.00%) 50.00% (15.00–85.00%) 50.00% (15.00–85.00%) 1.000
I 90.91% (60.09–99.99%) 90.91% (60.09–99.99%) 90.91% (60.09–99.99%) 1.000
II 85.71% (67.89–94.92%) 85.71% (67.89–94.92%) 82.14% (63.94–92.59%) 0.913
III 88.24% (72.78–95.93%) 82.35% (66.11–92.03%) 88.24% (72.78–95.93%) 0.718
IV 100.00% (29.02–100.00%) 100.00% (29.02–100.00%) 100.00% (29.02–100.00%) /
Not determined 91.30% (72.03–98.75%) 82.61% (62.26–93.63%) 86.96% (67.03–96.31%) 0.682